Autologous Mesenchymal Stem Cells, Applied in a Bioabsorbable Matrix, for Treatment of Perianal Fistulas in Patients With Crohn's Disease

Allan B Dietz, Eric Dozois, Joel Garland Fletcher, Greg W. Butler, Darcie Radel, Amy Lightner, Maneesh Dave, Jessica Friton, Asha Nair, Emily T. Camilleri, Amel Dudakovic, Andre J van Wijnen, William Alvis Faubion

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

In patients with Crohn's disease, perianal fistulas recur frequently, causing substantial morbidity. We performed a 12-patient, 6-month, phase 1 trial to determine whether autologous mesenchymal stem cells, applied in a bioabsorbable matrix, can heal the fistula. Fistula repair was not associated with any serious adverse events related to mesenchymal stem cells or plug placement. At 6 months, 10 of 12 patients (83%) had complete clinical healing and radiographic markers of response. We found placement of mesenchymal stem cell−coated matrix fistula plugs in 12 patients with chronic perianal fistulas to be safe and lead to clinical healing and radiographic response in 10 patients. ClinicalTrials.gov Identifier: NCT01915927.

Original languageEnglish (US)
Pages (from-to)59-62.e2
JournalGastroenterology
Volume153
Issue number1
DOIs
StatePublished - Jul 1 2017

    Fingerprint

Keywords

  • Cell Therapy
  • Clinical Trial
  • IBD
  • STOMP Trial

ASJC Scopus subject areas

  • Gastroenterology

Cite this